

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				2.	2. Issuer Name and Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Gerst Diane G.					Amphastar Pharmaceuticals, Inc. [_X_ Director	лісаотс)	10%	6 Owner	
(Last)) (First	t) (Mic	idle)				liest Trans	acti	on (MM	/DD/YYY	Y)	Officer (giv	e title below) Oth	er (specify b	pelow)
C/O AMPH							7/ 1	11/2	2022							
PHARMAC 6TH STREE	ET	•	., 1157()												
	(Stre	eet)		4.	If An	nendm	ent, Date (Orig	inal Fil	ed (MM/I	DD/YYYY)	6. Individual o	or Joint/G	oup Filing	(Check Appl	icable Line)
RANCHO C		ONGA, C		0								X Form filed by	y One Repor More than C	ting Person One Reporting P	erson	
			Table I -	Non-De	rivat	ive Sec	curities Ac	cqui	red, D	isposed	of, or Ben	eficially Owne	d			
1.Title of Security (Instr. 3) 2. Trans. Da				2A. Deemed Execution Date, if any		3. Trans. Code (Instr. 8)		Dispose	ities Acqui d of (D) , 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)				7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D)	Price				(I) (Instr. 4)	(IIISU. 4)
Common Stock 7/11/2022			11/2022			M		1521	A	\$20.08	14363			D		
Common Stock 7/11/2022				11/2022			S(1)		1521	D	\$36.2557 ⁽²⁾	12842			D	
	Tak	ole II - Deri	ivative So	ecurities	Bene	eficiall	y Owned	(e.g.	., puts,	calls, w	arrants, c	options, conver	tible secu	rities)		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deeme Execution Date, if any	4. Trans Code (Instr. 8		Derivat Acquire Dispose	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Oate Exer I Expirati		7. Title and Securities U Derivative (Instr. 3 and	Security	Derivative Security	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form of Derivative Security: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Sourity			Code	v	(A)	(D)	Dat Exe	te ercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect	
Stock Option (right to buy)	\$20.08	7/11/2022		M			1521		(3)	6/8/2028	Common Stock	1521	\$0	2856	D	

Explanation of Responses:

- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.81 to \$36.435, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- (3) Shares subject to the option are fully vested and immediately exercisable.

Reporting Owners

Reporting Owners							
Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director 10% Owner Office		Officer	Other			
Gerst Diane G.							
C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET	X						
RANCHO CUCAMONGA CA 91730							

Signatures

/s/ Eva Wen, by power of attorney

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.